Over a number of years the Therapeutic Goods Administration (TGA) and the complementary medicines
industry have recognised difficulties in appropriately quantifying the activity of enzymes used as active
ingredients in listed medicines. One difficult aspect has been in establishing an appropriate unit for the
enzyme activity of the improved ingredient ‘bromelains’ (Australian Approved Name).
As such the CHC seeks industry feedback on the attached proposal to assist in the resolution of this issue.

Please provide any comments to the CHC by COB Thursday, 24 October.

Click here to read the Alert.